Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation.

Abstract

A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.

• Authors: R E Steg, A Kessinger, Z K Wszolek
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 23 Issue 9 Pg. 959-62 (May 1999) ISSN: 0268-3369 [Print] England
• PMID: 10338054 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunosuppressive Agents
• Tacrolimus

Topics

• Blindness, Cortical (chemically induced)
• Bone Marrow Transplantation
• Female
• Graft Rejection (prevention & control)
• Humans
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Middle Aged
• Seizures (chemically induced)
• Tacrolimus (adverse effects, therapeutic use)
• Transplantation, Homologous